Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019042383) CRYSTALLINE FORMS OF GALUNISERTIB, PREPARATION METHOD THEREFOR, AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/042383 International Application No.: PCT/CN2018/103414
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
C07D 487/04 (2006.01) ,A61K 31/4709 (2006.01) ,A61K 31/4162 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4709
Non-condensed quinolines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4162
condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
苏州科睿思制药有限公司 CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD. [CN/CN]; 中国江苏省苏州市 工业园区星湖街218号生物纳米园B4-301赵林林 ZHAO, Linlin B4-301, Biobay, 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215123, CN
Inventors:
陈敏华 CHEN, Minhua; CN
张炎锋 ZHANG, Yanfeng; CN
高慧 GAO, Hui; CN
陈宇浩 CHEN, Yuhao; CN
张晓宇 ZHANG, Xiaoyu; CN
刘佳佳 LIU, Jiajia; CN
Priority Data:
201710769008.831.08.2017CN
Title (EN) CRYSTALLINE FORMS OF GALUNISERTIB, PREPARATION METHOD THEREFOR, AND USE THEREOF
(FR) FORMES CRISTALLINE DE GALUNISERTIB, PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉS
(ZH) Galunisertib的晶型及其制备方法和用途
Abstract:
(EN) The present invention relates to a crystalline form L, a crystalline form H, and a crystalline form N of galunisertib, a preparation method therefor, and a use thereof, a pharmaceutical composition containing the crystalline forms, and a use of the crystalline forms for preparing a pharmaceutical preparation for the treatment of myelodysplastic syndrome. The crystalline form L, the crystalline form H, and the crystalline form N provided by the present invention have one or more improved characteristics over those in the prior art and are of great value for future optimization and development of the drug.
(FR) La présente invention concerne une forme cristalline L, une forme cristalline H, et une forme cristalline N de galunisertib, un procédé de préparation associé et une utilisation correspondante, une composition pharmaceutique contenant les formes cristallines, et une utilisation des formes cristallines pour préparer une préparation pharmaceutique destinée à être utilisée dans le traitement du syndrome myélodysplasique. La forme cristalline L, la forme cristalline H et la forme cristalline N fournies par la présente invention possèdent une ou plusieurs caractéristiques améliorées par rapport à celles de l'état de la technique et sont d'une grande valeur pour l'optimisation et le développement futurs du médicament.
(ZH) 本发明涉及Galunisertib的晶型L、晶型H、晶型N及其制备方法和用途,含有该晶型的药物组合物,以及该晶型在制备治疗骨髓增生异常综合症药物制剂中的用途。本发明提供的晶型L、晶型H及晶型N比现有技术具有一种或多种改进的特性,对未来该药物的优化和开发具有重要价值。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)